Home » Thought Leadership » Blogs

Blogs

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 18 posts
September 1, 2021 | Blogs

Exploring the Impact of COVID-Driven Trends on the US Healthcare Landscape

CBPartners reviews the COVID-driven changes to patients, providers, payers, clinical research, and pharmaceutical distribution within the US.

CMS Hospital Pricing Transparency
August 2, 2021 | Blogs

CMS Hospital Pricing Transparency: One Price Fits All?

A CMS regulation from the Trump Administration requires hospitals to post lists containing the list price, negotiated private payer prices, and self-pay rates for up to 300 shoppable services took effect in January 2021, with the rule still being widely ignored by hospitals.

September 22, 2020 | Blogs

CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.

September 17, 2020 | Blogs

Hitting the Mark: Lessons Learned From Blockbuster Drugs That Missed or Exceeded Analyst Expectations

Pharmaceutical products can both exceed and fall short of blockbuster sales expectations by considerable margins which can be a result of a number of reasons. Some of these include the value of first-to-market dynamics, supporting real-world evidence to gain a competitive edge, and continual investment in trials for follow-on indications to improve life cycle management.

July 6, 2020 | Blogs

What’s Next for Alzheimer’s Disease?

Basic science has been redeployed to establish a new understanding of Alzheimer's Disease, focusing on novel biomarkers and cutting-edge therapeutic approaches to slow or reverse disease progression, where the amyloid beta theory has otherwise failed